Industry News
Biotechnology Industry News
Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact
Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact ntaylor Wed, 04/06/2022 - 06:49
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda gmasson Tue, 04/05/2022 - 17:29
Merck looks to cardiovascular pipeline for $10B-plus peak sales—and diversification from Keytruda
Merck looks to cardiovascular pipeline for $10B-plus peak sales—and diversification from Keytruda gmasson Tue, 04/05/2022 - 17:29
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021 aarmstrong Tue, 04/05/2022 - 13:56
String of NIH departures continues as Ned Sharpless, head of the National Cancer Institute, steps down
String of NIH departures continues as Ned Sharpless, head of the National Cancer Institute, steps down mbayer Tue, 04/05/2022 - 09:54
Takeda’s gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks
Takeda's gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks aarmstrong Tue, 04/05/2022 - 09:02
Phase 3 rare disease failure extends Theravance’s losing streak
Phase 3 rare disease failure extends Theravance's losing streak ntaylor Tue, 04/05/2022 - 08:38
Imara flunks phase 2b trials in sickle cell and thalassemia, wiping out clinical pipeline
Imara flunks phase 2b trials in sickle cell and thalassemia, wiping out clinical pipeline ntaylor Tue, 04/05/2022 - 07:48
Rough biotech market won’t stop 5AM Ventures’ new $750M life science funds
Rough biotech market won't stop 5AM Ventures' new $750M life science funds gmasson Mon, 04/04/2022 - 17:23
As FDA funding debated, CDER chief makes a pitch for more scientists—not a reorganization
As FDA funding debated, CDER chief makes a pitch for more scientists—not a reorganization mbayer Mon, 04/04/2022 - 17:18
CRISPR patent dispute not over yet as Emmanuelle Charpentier, universities appeal
CRISPR patent dispute not over yet as Emmanuelle Charpentier, universities appeal aarmstrong Mon, 04/04/2022 - 16:12
Through ‘serial de-risking,’ Sage is getting closer to building an Alzheimer’s contender
Through 'serial de-risking,' Sage is getting closer to building an Alzheimer's contender aarmstrong Mon, 04/04/2022 - 15:31
ACC: Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2b
ACC: Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2b mbayer Mon, 04/04/2022 - 10:21
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments aarmstrong Mon, 04/04/2022 - 09:47
Obesity may alter inflammation on a molecular level, throwing current treatments into question
Obesity may alter inflammation on a molecular level, throwing current treatments into question mbayer Mon, 04/04/2022 - 08:28
FDA puts Curis’ leukemia trial on partial hold after patient death spurs review of muscle breakdown
FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown ntaylor Mon, 04/04/2022 - 07:54
Novartis says bye to Tsai as restructuring triggers the return of a familiar face
Novartis says bye to Tsai as restructuring triggers the return of a familiar face ntaylor Mon, 04/04/2022 - 04:54
Legend Biotech CSO abruptly leaves Johnson & Johnson’s CAR-T partner he co-founded
Legend Biotech CSO abruptly leaves Johnson & Johnson's CAR-T partner he co-founded aliu Fri, 04/01/2022 - 21:11
SAB vows to plow ahead with COVID-19 therapy after NIH drops out
SAB vows to plow ahead with COVID-19 therapy after NIH drops out aarmstrong Fri, 04/01/2022 - 10:06
Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024
Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024 mbayer Fri, 04/01/2022 - 10:02